ALK and neoplasm: Fourthly, tumor mutation-driver genes such as EGFR, ALK, and ROS1 and the use of targeted therapies were not recorded in the SEER data, and reflecting the time period of this study, neither were tumor PDL-1 status and the use of immunotherapy.